Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: Comparison to sibutramine

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 10, 2011, Pages 1187-1195

  Abo Elmatty, D M ^a   Zaitone, Sawsan A ^a  

^a Suez Canal University   (Egypt)

Author keywords

Anxiety; Blood pressure; Obesity; Topiramate; Weight control

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GLUCOSE; INSULIN; LEPTIN; LIPID; SIBUTRAMINE; TOPIRAMATE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTERIAL PRESSURE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID DIET; NONHUMAN; OBESITY; RAT; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CYCLOBUTANES; FEMALE; FRUCTOSE; INSULIN; INSULIN RESISTANCE; LEPTIN; LIPIDS; OBESITY; RATS; WEIGHT LOSS;

EID: 82455174227     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. JEWETT DC, HAHN TW, SMITH TR, FIKSDAL BL, WIEBELHAUS JM, DUNBAR AR, et al. Effects of sibutramine and rimonabant in rats trained to discriminate between 22- and 2-h food deprivation. Psychopharmacol 2009; 203: 453-459.
2. HALFORD JCG. Pharmacotherapy for obesity. Appetite 2006; 46: 6-10.
3. MCNEELY W, GOA KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56: 1093-1124.
4. NISOLI E, CARRUBA MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Safety 2003; 26: 1027-1048.
5. BINKLEY K, KNOWLES SR. Sibutramine and panic attacks. Am J Psychiatr 2002; 159: 1793-1794.
6. CHAPUT JP, ST-PIERRE S, TREMBLAY A. Currently available drugs for treatment of obesity: sibutramine and orlistat. Med Chem 2007; 7: 3-10.
7. MARCOTTE D. Use of Topiramate: a new antiepileptic drug as a mood stabilizer. J Aff Disord 1998; 50: 245-251.
8. REIFE R, PLEDGER G, WU SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000; 41: S66-S71.
9. RICHARD D, PICARD F, LEMIEUX C, LALONDE C, SAMSON P, DESHAIES Y. The effect of topiramate and sex hormones on energy balance of male and femal rats. Int J Obes Relat Metab Disord 2002; 3: 344-353.
10. SRINIVASAN K, VISWANAD B, ASRAT L, KAUL CL, RAMARAO P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rats: A model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005; 52: 313-320.
11. HANSEN HH, HANSEN G, TANG-CHRISTENSEN M, LARSEN PJ, AXEL AM, RABEN A, MIKKELSEN JD. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant. Eur J Pharmacol 2010; 636: 88-95.
12. JING LI, DAN LI, SHAW-BING H. Effects of topiramate and valproic acid on serum insulin and leptin levels in young and adult rats. Chin J Contemp Pediatr 2007; 9: 229-232.
13. PETERSEN MN, LASSEN YB. A water lick conflict paradigm using experimental rats. Psychopharmacol 1979; 75: 236-239.
14. VOGEL J, BEER B, CLODY D. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacol 1971; 21: 1-7.
15. ORLOWSKI JP, ERENBERG G, LUEDERS H, CRUSE RP. Hypothermia and barbiturate coma for refractory status epilepticus. Crit Care Med 1984; 12: 367-372.
16. FITZGERALD SM, MICHAEL W. Brands Nitric oxide may be required to prevent hypertension at the onset of diabetes. Am J Physiol Endocrinol Metab 2000; 279: E762-E768.
17. RISTOW M, MULDER H, POMPLUN D, SCHULZ TJ, MULLER-SCHMEHL K, KRAUSE A, FEX M, PUCCIO H, MÜLLER J, ISKEN F, SPRANGER J, MÜLLER-WIELAND D, MAGNUSON MA, MOHLIG M, KOENIG M, PFEIFFER AF. Frataxin deficiency in pancreatic islets causes diabetes due to loss of beta cell mass. J Clin Invest 2003; 112: 527-534.
18. MIZUNO TM, KELLEY KA, PASINETTI GM, ROBERTS JL, MOBBS CV. Transgenic neuronal expressionof proopiomelanocortin attenuates hyperphagic response to fasting and reverses metabolic impairments in leptin-deficient obese mice. Diabetes 2003; 52: 2675-2683.
19. MEADA K, OKUBO K, SHIMOMURA I. CDNA CLONING and expression of a novel adipose specific collagen-like factor, apM 1 (adipose most abundant gene transcript 1). Biochem Biophy Res Commun 1996; 221: 286-289.
20. TRINDER P. Determination of blood glucose using 4-amino phenazone as oxygen acceptor. J Clin Pathol 1969; 22: 246.
21. THE STUDY GROUP EUROPEAN ATHEROSCLEROSIS SOCIETY. Lipid and lipoprotein determination. Eur Heart J 1988; 9: 571-600.
22. HUA C, LI-JUN L, JIAN-JUN Z, BO X, RUI L. Effect of soybean oligosaccharides on blood lipid, glucose levels and antioxidant enzymes activity in high fat rats. Food Chem 2009; 4: 1633-1639.
23. MATTHEWS DR, HOSKER JP, RUDENSKI AS, NAYLOR BA, TREACHER DF, TURNER RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
24. KATZ A, NAMBI SS, MATHER K, BARON AD, FOLLMANN DA, SULLIVAN G, QUON MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410.
25. STROUBINI T, PERELAS A, LIAPI C, PERREA D, DONTAS I, TZAVARA C. Serum adiponectin and resistin in rats under three isocaloric diets: The effect of sibutramine. Cytokine 2009; 46: 171-175.
26. SRINIVASAN K, PATOLE PS, KAUL CL, RAMARAO P. Reversal of glucose intolerance by by pioglitazone in high fat diet-fed rats. Meth Find Exp Clin Pharmacol 2004; 26: 327-333.
27. REDA TK, GELIEBTER A, PI-SUNYER FX. Amylin, food intake and obesity. Obes Res 2002; 10: 1087-1091.
28. THORBURN AW, AINSLIE DA, FAM B, PROIETTO J. Leptin in the pathophysiology of human obesity and the clinical potential of leptin-based therapy. Bio Drugs 2000; 6: 391-396.
29. UNGER RH, ZHOU YT, ORCI L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci USA 1999; 96: 2327-2332.
30. CAMPFIELD LA, SMITH FJ, GUISEZ Y, DEVOS R, BURN P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546-549.
31. ZHANG Y, PROENCA R, MAFFEI M, BARONE M, LEOPOLD L, FRIEDMAN JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
32. WANG Q, BING C, AL-BARAZANJI K, MOSSAKOWASKA DE, WANG XM, MCBAY DL, NEVILLE WA, TADDAYON M, PICKAVANCE L, DRYDEN S, THOMAS ME, MCHALE MT, GLOYER IS, WILSON S, BUCKINGHAM R, ARCH JR, TRAYHURN P, WILLIAMS G. Interactions between leptin and hypothalamic neuropeptide Y neurons in the control of food intake and energy homeostasis in the rat. Diabetes 1997; 46: 335-341.
33. CARO JF, KOLACZYNSKI JW, NYCE MR, OHANNESIAN JP, OPENTANOVA I, GOLDMAN WH, LYNN RB, ZHANG PL, SINHA MK, CONSIDINE RV. Decreased cerebrospinal-fluid/ serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159-161.
34. SELENSCIG D, ROSSI A, CHICCO A, LOMBARDO YB. Increased leptin storage with altered leptin secretion from adipocytes of rats with sucrose-induced dyslipidemia and insulin resistance: effect of dietary fish oil. Metabolism 2010; 59: 787-795.
35. LOPEZ IP, MILAGRO FI, MARTI A, MORENO-ALIAGA MJ, MARTINEZ JA, DE MIGUEL C. High-fat feeding period affects gene expression in rat white adipose tissue. Mol Cell Biochem 2005; 275: 109-115.
36. MAEBUCHI M, MACHIDORI M, URADE R, OGAWA T, MORIYAMA T. Low resistin levels in adipose tissues and serum in high-fat fed mice and genetically obese mice: development of an ELISA system for quantification of resistin. Arch Biochem Biophysic 2003; 416: 109-115.
37. TALLETT AJ, BLUNDELL JE, RODGERS RJ. Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats. Pharmacol Biochem Behav 2010; 97: 92-100.
38. TALLETT AJ, BLUNDELL JE, RODGERS RJ. Sibutramine and naloxone: infra-additive interaction in the regulation of appetite. Behav Brain Res 2010; 207: 174-181.
39. TZIOMALOS K, KRASSAS GE, TZOTZAS T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag 2009; 5: 441-452.
40. BERKOWITZ RI, WADDEN TA, TERSHAKOVEC AM, CRONQUIST JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003; 289: 1805-1812.
41. KIM SH, LEE YM, JEE HJ, NAM CM. Effect of sibutramine on weight loss and blood pressure: a metanalysis of controlled trials. Obes Res 2003; 11: 1116-1123.
42. SCHOLZE J, GRIMM E, HERRMANN D, UNGER T, KINTSCHER U. Optimal treatment of obesity-related hypertension, the hypertension-obesity-sibutramine (HOS) study. Circulation 2007; 115: 1991-1998.
43. MARTIN KF, HANNON SD, CZUDEK C, HEAL DJ, BUCKETT WR. Comparison of the effect of sibutramine and d-amphetamine on extracellular dopamine levels in rat nucleus accumbens: an in vivo microdialysis study. Br J Pharmacol 1995; 114: 346.
44. WOOLTORTON E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002; 166: 1307-1308.
45. BIRKENFELD AL, SCHROEDER C, BOSCHMANN M. Paradoxical Effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002; 106: 2459-2465.
46. DEROSA G, D'ANGELO A, SALVADEO SA, FERRARI I, GRAVINA A, FOGARI E, MAFFIOLI P, CICERO AF. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism 2008; 57: 1552-1557.
47. TAFLINSKI T, CHOJNACKA J. Sibutramine-associated psychotic episode. Am J Psychiatr 2000; 157:2057-2058.
48. BENAZZI F. Organic hypomania secondary to sibutramine-citalopram interaction. J. Clin Psychiatr 2002; 63: 165-169.
49. CORDEIRO Q, VALLADA H. Sibutramine-induced mania episode in a bipolar patient. Int J Neuropsychopharmacol 2002; 5: 283-284.
50. FIORENTINI S, RUSSO DD, AMALO A, LIMPIDO L, BERSANI G. Sibutramine-related panic attack: a clinical case of apparent resolution with paroxetine. Riv Psychiatr 2009; 1: 64-67.
51. WILKES JJ, NELSON E, OSBORNE M, DEMAREST KT, OLEFSKY JM. Topiramate is an insulin sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 2004; 10: 1-35.
52. RICHARD D, FERLAND J, LALONDE J, SAMSON P, DESHAIES Y. Influence of topiramate in the regulation of energy balance. Nutrition 2000; 16: 961-966.
53. TONSTAD S, TYKARSKI A, WEISSGARTEN J, IVLEVA A, LEVY B, KUMAR A, FITCHET M. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 2005; 35: 243-251.
54. YORK DA, SINGER L, THOMAS S, BRAY GA. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptides, and uncoupling-protein mRNAs. Nutrition 2000; 16: 967-975.
55. MCELROY SL, ARNOLD LM, SHAPIRA NA, KECK PE JR, ROSENTHAL NR, KARIM MR, KAMIN M, HUDSON JI. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatr 2003; 160: 255-261.
56. ZHENG H, PATTERSON C, BERTHOUD HR. Behavioral analysis of anorexia produced by hindbrain injections of AMPA receptor antagonist NBQX in rats. Am J Physiol Reg Integ Comp Physiol 2002; 282: R147-R155.